Abstract: The lifetime risk of having epileptic seizures is profoundly increased in patients with cancer: about 20% of all patients with systemic cancer may develop brain metastases. These patients and those with primary brain tumours have a lifetime risk of epilepsy of 20-80%. Moreover, exposure to chemotherapy or radiotherapy to the brain, cancer-related metabolic disturbances, stroke, and infection can provoke seizures. The management of epilepsy in patients with cancer includes diagnosis and treatment of the underlying cerebral pathological changes, secondary prophylaxis with antiepileptic drugs, and limiting of the effect of epilepsy and its treatment on the efficacy and tolerability of anticancer treatments, cognitive function, and quality of life. Because of the concern of drug-drug interactions, the pharmacological approach to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly increasing choices of agents both to treat cancer and cancer-associated epilepsy. GABA, -aminobutyric acid; HDAC, histone deacetylase; MRI, magnetic resonance imaging; SV2A, synaptic vesicle 2A.
Introduction
Epileptic seizures are a potentially life-threatening symptom of structural or metabolic brain dysfunction. They are among the most common presenting features of patients with primary brain tumors. They are also a frequent complication in patients with disseminated cancer, mostly because of solid brain metastasis or leptomeningeal disease, but may also be caused by exposure to chemotherapy or radiotherapy to the brain, stroke, infection, or general disturbances e.g. of salt or liver metabolism associated with systemic cancer progression. This review focuses on the relevance of epilepsy for clinical oncology with specific consideration of the practical management of epilepsy in cancer patients as well as the increasingly complex interactions between the pharmacological approaches to cancer versus cancer-associated epilepsy. For specific aspects related to epilepsy and cancer, the reader is referred to contemporary review articles on epilepsy in primary brain tumor patients, 1,2 drug drug interactions 3, 4 and drugresistant epilepsy.
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Seizures and epilepsy: their nature and classification
An epileptic seizure is most often a transient event caused by abnormal excessive or synchronous neuronal activity in the brain and can often, but not always, be recognized clinically by symptoms and signs of neurological dysfunction, most commonly altered consciousness and uncontrolled motor activity. As such, seizures can occur in the presence of a transitory precipitating factor, e.g., metabolic disturbance or exposure to a proconvulsive agent, including anti-cancer pharmaceutics, and are then a symptom of an underlying condition. Epilepsy, in contrast, is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures in the absence or presence of an underlying structural brain alteration. Accordingly, there are classifications of epileptic seizures as well as classifications of epileptic disorders. 6 The distinction of seizures and epilepsy remains difficult in the context of brain tumors. In general, seizures can, as a symptom, herald the development of any structural brain disease and are then also best conceived as being symptomatic, e.g., of a brain tumor. Some patients suffer a single seizure that leads to the diagnosis of a benign tumor that can be resected, and the patient will never suffer a seizure again. In other patients, tumors remain stable with or without specific oncological treatment, but seizure control becomes a life-long therapeutic challenge.
It is estimated that approximately 50 million people worldwide suffer from some form of epilepsy, with a lifetime risk of one in 10 individuals to experience at least one seizure.
In infants, seizures more often reflect an epileptic disorder without identifiable morphological brain pathology whereas in adults and in particular in the elderly seizures are commonly the first symptom of an underlying structural brain alteration. Cancer patients typically suffer either tonic-clonic generalized seizures that may be secondary to a focal seizure when they have structural brain lesions, which is more common, or not when they are triggered, e.g., by metabolic disturbances or exposure to proconvulsive agents, including anti-cancer pharmaceutics. rashes, drowsiness and cognitive alterations may severely affect quality of life.
Interfaces of epilepsy and cancer
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Unwanted effects from AED may also be more common in (brain) cancer patients than in patients with other etiologies of epilepsy. 13 This has most likely multiple reasons, notably comedications such as steroids and chemotherapy, but also exposure to radiotherapy as well as effects of the tumor itself, and psychiatric comorbidity, notably depression. Of note, cognitive side effects from AED have to be weighed against cognitive deterioration induced by seizures, which can be severe and prolonged, too. If AED are indicated following the guidelines below, it is recommended to use non-EI-AED rather than EI-AED and to dose a single agent adequately high, that is to the edge of the recommended dose without unwanted effects, before moving to double or triple AED combinations, which are more difficult to monitor in terms of drug drug interactions, tolerability, safety, and efficacy. There is no evidence that specific AED are more active than others in brain tumor-associated epilepsy. Formal comparative trials of AED specifically in brain tumors have rarely been conducted, and the primary choice of agent varies among experts. The SANAD trials that had indicated preferential activity of lamotrigine in focal epilepsy and of valproic acid in generalized epilepsy 14, 15 cannot be simply extrapolated to patients with brain tumors. In the absence of randomized studies in the brain tumor population of patients with epilepsy, preferred drugs based on tolerability, interactions, and efficacy at present include valproic acid, levetiracetam, 16, 17 lamotrigine, 18 and possibly lacosamide. 19 Expression of synaptic vesicle protein 2A
(SV2A), the presumed target of levetiracetam, may predict response to the drug. 20 Drug combinations that may be useful in cancer patients with epilepsy include valproic acid plus lamotrigine or levetiracetam or levetiracetam plus topiramate. 18 The local delivery of AED via convection-enhanced delivery is feasible, but plays no role in clinical practice.
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Are cancer patients at increased risk of epilepsy in the absence of CNS involvement?
The most common cause of seizures in cancer patients is probably the development of solid brain metastases, 9 but leptomeningeal involvement needs also consideration.
Accordingly, the initial work-up of a first seizure in any cancer patient must include neuroimaging, preferably MRI to rule out brain metastases. Neuroimaging, however, may also reveal stroke or infectious complications, which may be more common in 
Epilepsy in primary brain tumor patients
The life-time incidence of epileptic seizures in patients with primary brain tumors varies by diagnosis, age and literature source and is estimated in the range of 20-80%. The incidence is relatively lower in some of the most malignant brain tumors such as glioblastoma and primary central nervous system (CNS) lymphoma, but higher in some more benign, but still infiltrative lesions such as World Health Organization (WHO) grade II diffuse gliomas. The reasons for these differences are multifold, but remain somewhat speculative. Typical features attributed a high seizure risk include location in the temporal lobe and cortical as opposed to white matter involvement. In this regard, oligodendroglial tumors are often located at the interface between cortex and white matter and cause seizures frequently whereas primary CNS lymphomas are more commonly growing in the white matter and are usually not diagnosed because of an epileptic seizure. In some types of brain tumors such as dysembryoplastic neuroepithelial tumors, the natural course of the tumor is very benign, but the severity of epilepsy dictates the necessity for surgical intervention. 23 In such instances, surgery
should be performed at centers specialized in epilepsy surgery. In low-grade gliomas, complete resection, shorter seizure history < 1 year, seizures other than focal seizures, and previous seizure response to pharmacotherapy were associated with better seizure control after surgery. 24 In general, surgical tumor resection may greatly contribute to the reduction of seizure frequency and severity in patients with brain tumor-associated epilepsy. Beyond surgical resection, 25, 26 other anti-tumor treatments such as radiotherapy and chemotherapy may improve seizure control e.g. in patients with lowgrade gliomas. 27 Some patients treated with temozolomide chemotherapy report improvement of seizure frequency well before any objective tumor regression is demonstrated by neuroimaging. Another compelling example of a nonsurgical anti-tumor treatment that helped to improve epilepsy in more than half of patients was recently provided by the introduction of the mTOR inhibitor, everolimus, as an experimental agent to inhibit the growth of subependymal giant cell astrocytomas in patients with tuberous sclerosis. 28 The rationale for everolimus is enhanced mTOR activity resulting from lack of upstream control exerted by the tuberin/harmartin complex. 
Do AED exhibit intrinsic anti-tumor properties?
Intrinsic antitumor activity of certain AED and synergy with chemotherapy or radiotherapy have been suggested in some, but not all studies. For instance, phenytoin has been attributed anti-mitotic and anti-invasive properties, and valproic acid has been suggested to induce cell differentiation, growth arrest, apoptosis, autophagy, and these effects were proposed to be mediated by histone deacetylase (HDAC) inhibitory properties. [36] [37] [38] [39] [40] These issues were most often addressed in the context of gliomas, given the high need for AED treatment in this patient population. We did not observe cytotoxic or antiproliferative effects of either carbamazepine, phenytoin or valproic acid in cultured glioma cells at concentrations likely to be achieved in vivo. 41 Yet, valproic acid alone delayed growth in medulloblastoma xenograft models in severe combined immunodeficiency mice in the apparent absence of relevant systemic toxicity, 37 but because of differences in valproic acid metabolism of valproic acid in mouse and man, these interesting observations in mice are difficult to extrapolate to human patients.
Moreover, valproic acid when combined with the DNA (cytosine-5) methyltransferase inhibitor 5-aza-2'-deoxycytidine reduced the incidence of medulloblastomas and rhabdomyosarcomas in heterozygous Patched 1 knockout mice. 38 The same combination induced expression of the candidate tumor antigen NY-ESO-1 in cultured glioma cells. 39 If AED act via HDAC inhibition only to potentially inhibit tumor growth when administered alone, their antitumor activity can be predicted to be low, given that much more powerful HDAC inhibitors have shown rather limited single agent activity in human cancer patients.
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Interactions of cancer therapy and AED: tolerability
Pharmacokinetic as opposed to pharmacodynamic interactions of AED and various anticancer drugs are the most important area to consider for the general oncologist at the interface between cancer care and epilepsy. 3, 4 Although many AED are metabolized in the liver, only certain agents like phenytoin, carbamazepine and derivatives, and phenobarbital, induce CYP450-dependent hepatic enzymes and thus increase their own metabolism and more importantly, the metabolism and degradation of many commonly used cytotoxic agents ( Table 2 These require regular up-dating. Importantly, the risk of using such EI-AED does not only include the risk of delivering expensive, but necessarily ineffective medical cancer therapy, but also a sudden increase in toxicity and loss of tolerability when such EI-AED are withdrawn and replaced by non-EI-AED. Thus, special attention to drug drug interactions is required not only when implementing, but also when tapering AED.
Conversely, the enzyme-inhibiting effect of valproic acid appears clinically of lesser importance, although increased myelosuppression may develop in patients receiving nitrosoureas or cisplatinum-based chemotherapy or temozolomide concomitantly with valproic acid. 43, 44 There are also safety concerns regarding the choice of AED in cancer patients beyond drug-drug interactions. Various neurosurgeons fear an increased risk of peri-operative bleeding complications in valproic acid-treated brain tumor patients, although this is not supported by the literature. 45, 46 The risk of severe skin toxicity is increased when patients are treated with phenytoin or carbamazepine or oxcarbazepine not only in combination with procarbazine, but also with radiotherapy. 47 Finally, EI-AED decrease the bioavailability of steroids, necessitating careful clinical monitoring when EI-AED are newly introduced in steroid-dependent brain tumor patients. Conversely, when EI-AED are replaced by non-EI-AED, it should be assessed whether steroid doses can be lowered. Based on these considerations and the unfavorable safety profile of these drugs regarding cognitive function, we propose to select a priori newer AED, which are devoid of such interactions.
Interactions of cancer therapy and AED: efficacy and survival
Because of the enzyme-inducing activity described above, older AED such as phenytoin, phenobarbital or carbamazepine may enhance the metabolism of many commonly administered chemotherapy agents and thus decrease their efficacy (Table   2) . Accordingly, there is now a trend to favor non-EI-AED for cancer patients, in order to allow effectively the administration of chemotherapy and targeted agents that often show increased hepatic metabolism in EI-AED-treated patients. Conversely, it has not been demonstrated that the enzyme inhibitory activity of valproic acid results in clinically relevant increases in anti-cancer drug levels and that this increases their activity through a pharmacokinetic mechanism. -methylguanine-DNA-methyltransferase expression, 48 thus targeting one of the major resistance pathways of alkylating agent chemotherapy. 49 Since the life-time risks of glioblastoma patients to experience epileptic seizures as well as AED-associated toxicity are considerable, and since these patients are now commonly exposed to chemotherapy, there has traditionally been significant interest in the choice of AED in glioblastoma. A retrospective analysis of three trials performed by the North Central Cancer Treatment Group indicated a possible association of EI-AED use, but not of seizure history, with a favorable outcome in glioblastoma patients. 50 Yet, the implications of this observation remain unclear in that the chemotherapy regimens used in these trials are not considered active. 51 Accordingly, we retrospectively assessed a potential predictive association with outcome of AED use within the pivotal trial of radiotherapy alone versus radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma that was conducted by the European
Organization for Research and Treatment of Cancer and the National Cancer Institute of
Canada Clinical Trials Group. 52 We identified 387 patients (68% of all patients) who received any AED; 110 patients (28% of those receiving AED) were prescribed exclusively non-EI-AED, mostly valproic acid, while the others received at least one EI-AED, either phenytoin, carbamazepine, oxcarbazepine, or phenobarbital. We specifically compared three groups of patients, those without AED, those treated with valproic acid alone, and those treated with EI-AED only. After controlling for potentially confounding factors, we still observed a significant increase in overall survival of patients treated with valproic acid in the experimental arm, but not in the radiotherapy arm, suggesting a specific interaction between valproic acid and temozolomide chemotherapy. This association remains after adjusting for potentially confounding factors and inbalances.
Moreover, hematological toxicity in patients treated with chemoradiotherapy and valproic acid was increased. 44 Nevertheless, our analysis has some limitations and should be interpreted with caution. The data were generated from an unplanned and insufficiently HDAC inhibition could be achieved in vivo. 56 Yet, a phase I trial exploring valproic acid plus dacarbazine/interferon- chemoimmunotherapy in metastatic melanoma showed only moderate tolerability, but no indication of enhanced activity. 57 Exploratory trials using HDAC inhibitors more potent than valproic acid such as vorinostat in combination with temozolomide radiochemotherapy may provide further support for this hypothesis.
Selective HDAC inhibitors might also have a preferred tolerability profile compared with valproic acid, which induces weight gain, alopecia and tremor in some patients (Table   1 ). In any case, this analysis from a randomized phase III trial supports the view that the choice of AED in brain tumor patients may affect survival.
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Frequently asked questions (FAQ) regarding epilepsy and cancer
The interface between cancer and epilepsy currently provides an area of many interesting observations, active clinical and laboratory research, and opportunities to improve quality of life and outcome in cancer patients. Yet, there are at the same time many questions that arise in daily clinical practice and for many of which there are no answers that could be based on several or even one adequate clinical trial. Table 3 summarizes some of these classical questions (and answers). Improved cancer therapy, as well as early and regular prenatal care, allow normal pregnancies and pregnant women with cancer to deliver healthy babies. Here it may be important to attempt decreasing pharmacotherapy to monotherapy and to taper doses of AED to the lowest possible level. There is no anticonvulsant of choice; however, the best safety data are available for lamotrigine. 58 In women who have not had a seizure for 2-5 years, an attempt at complete AED withdrawal is warranted. Patients should be offered preconceptual genetic counseling.
Almost a quarter of people diagnosed with epilepsy are >60 years of age. Underlying factors are discovered in a greater proportion than in younger patients, including cerebrovascular disease, dementia, trauma and tumors. Treatment should be kept at the lowest effective dose since there is an increased risk of side effects and idiosyncratic reactions. 59 There is an increased risk of pharmacological interactions due to polypharmacy. The likelihood and severity of adverse reactions is increased. Since longterm AED treatment is considered an independent risk factor for osteoporosis, calcium and vitamine D supplements should be considered with AED treatment in the elderly.
Further, epilepsy is associated with an increased risk of mental health disorders, such as anxiety, depression and suicidal thoughts. 
